US2018148449A1PendingUtilityA1
Substituted-Quinoxaline-Type Bridged-Piperidine Compounds and the Uses Thereof
Est. expiryJul 21, 2028(~2 yrs left)· nominal 20-yr term from priority
A61P 43/00A61P 9/12A61P 35/00A61P 29/00A61P 25/22A61P 25/04A61P 25/30A61P 25/24A61P 3/04A61P 3/00A61P 25/08A61P 25/00A61P 25/28A61P 25/16A61P 1/10A61P 1/12A61P 13/02A61P 13/00A61P 11/04A61P 11/14C07D 451/14C07D 471/08C07D 403/04A61K 31/498
62
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The invention relates to Substituted-Quinoxaline-Type Bridged-Piperidine Compounds, compositions comprising an effective amount of a Substituted-Quinoxaline-Type Bridged-Piperidine Compound and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective amount of a Substituted-Quinoxaline-Type Bridged-Piperidine Compound.
Claims
exact text as granted — not AI-modified1 - 46 . (canceled)
47 . A method for treating pain in an animal, comprising administering to an animal in need thereof an effective amount of a compound of Formula (I′):
or a pharmaceutically acceptable derivative thereof, wherein:
each R 2 is independently selected from -halo;
a is 0, 1 or 2;
b is 0 or 1;
each R 5 is independently —H, —OH, —(C 1 -C 3 )alkyl, —C(halo) 3 , or -halo;
R 1 is —(C 9 -C 14 )cycloalkyl or —(C 9 -C 14 )bicycloalkyl, each of which is substituted with 1, 2 or 3 independently selected R 3 groups;
each R 3 is independently —(C 1 -C 4 )alkyl, —(C 2 -C 6 )alkenyl, —(C 2 -C 6 )alkynyl, or —(C 3 -C 6 )cycloalkyl.
48 - 53 . (canceled)
54 . The method of claim 47 , wherein each R 5 is independently —H, —(C 1 -C 3 )alkyl, —C(halo) 3 , or -halo.
55 . The method of claim 47 , wherein each R 5 is independently —H, —CH 3 , —CF 3 , or —F.
56 . The method of claim 47 , wherein a is 0 or 1.
57 . The method of claim 47 , wherein the compound is a compound of formula (II):
or a pharmaceutically acceptable derivative thereof.
58 . The method of claim 57 , wherein the 3-oxo-3,4-dihydroquinoxaline-2-carboxylic acid portion of the compound is in the endo-conformation with respect to the bridge of the bridged piperidine.
59 . The method of claim 47 , wherein R 1 is —(C 9 -C 12 )cycloalkyl or —(C 9 -C 12 )bicycloalkyl.
60 . The method of claim 47 , wherein R 1 is -indanyl, -1,2,3,4-tetrahydronaphthalenyl, -5,6,7,8-tetrahydronaphthalenyl, -perhydronaphthalenyl, bicyclo[3.3.1]nonyl, bicyclo[4.2.1]nonyl, bicyclo[3.3.2]decyl, bicyclo[4.2.2]decyl, bicyclo[4.3.1]decyl, bicyclo[3.3.3]undecyl, bicyclo[4.3.2]undecyl, or bicyclo[4.3.3]dodecyl.
61 . The method of claim 47 , wherein R 1 is bicyclo[3.3.1]nonyl.
62 . The method of claim 61 , wherein R 1 is 2-bicyclo[3.3.1]nonyl or 3-bicyclo[3.3.1]nonyl.
63 . The method of claim 47 , wherein R 1 is in the endo-conformation with respect to the bridge of the bridged piperidine of the compound.
64 . The method of claim 47 , wherein b is 1.
65 . The method of claim 47 , wherein R 1 is
66 . The method of claim 47 , wherein said pain is said pain is acute pain or chronic pain.
67 . The method of claim 47 , wherein said pain is inflammatory pain, neuropathic pain, or a combination thereof.
68 . The method of claim 47 , wherein said compound is selected from the group consisting of
and pharmaceutically acceptable derivatives thereof.
69 . A method of treating pain in an animal, comprising administering to an animal identified in need thereof an effective amount of a compound of
or a pharmaceutically acceptable derivative thereof.
70 . The method of claim 69 , wherein said pain is acute pain or chronic pain.Join the waitlist — get patent alerts
Track US2018148449A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.